CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

Calumet shows strong potential as a long-term investment with growth opportunities and positive cash flows. Click here to ...

Jungheinrich's guidance remains steady, though risks persist. Find out why JGHAF stock's valuation suggests upside potential, ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

Financial writer recommends a soft buy rating on Brunswick Corporation despite recent underperformance. Click for this ...

Vanguard Growth Index Fund ETF Shares thrived in 2024, but economic changes raise concerns. See why we maintain a cautious ...

Datadog, Inc.s strong business and growth prospects are hindered by a steep valuation, making it a risky investment at ...

Palantir is susceptible to a general market decline, as earlier investors cash in on the bubble. Click here to find out why I ...

Quant titan Steven Cress shares his top stocks for 2025, beginning with Celestica (0:45). Intapp's very strong liquidity and ...

Learn why shares have sold off post weak Q3 results. Analysts project EPS growth in FY25 due to stable expenses and lower ...

Proximus PLC's fiber rollout and Digi's competition raise concerns. Find out why BGAOF stock requires a "wait and see" ...

The article discusses the impact of high treasury yields on the S&P 500, highlighting opportunities for patient investors ...